Related Experiment Video
Updated: Mar 31, 2026

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
Published on: April 14, 2016
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma
Evangelos Terpos1, Cyrille B Confavreux2, Philippe Clézardin3
1National and Kapodistrian University of Athens, School of Medicine , Athens, Greece.
Abstract:
Skeletal lesions contribute substantially to morbidity and mortality in patients with cancer. The disease manifestation course during metastatic bone disease is driven by tumour cells in the bone marrow, which alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction. Successful therapeutic strategies for the treatment of metastatic bone disease include bisphosphonates and denosumab that inhibit osteoclast-mediated bone resorption. Inhibitors of cathepsin K, Src and activin A are under clinical investigation as potential anti-osteolytics. In this review, we describe current knowledge and future directions of antiresorptive therapies that may reduce or prevent destructive bone lesions from solid tumours and multiple myeloma.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Remodeling
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Urinary Tract Calculi III: Medical Management
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

